Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
26/02/2026 17:41
Feb 26 (Reuters) - OSE Immunotherapeutics SA OSE.PA: OSE IMMUNOTHERAPEUTICS RECEIVES SECOND POSITIVE IDMC RECOMMENDATION FOR PHASE 3 ARTEMIA TRIAL EVALUATING TEDOPI® IN NON-SMALL CELL LUNG CANCER OSE IMMUNOTHERAPEUTICS SA: TEDOPI® NSCLC PIVOTAL PHASE 3 INTERIM FUTILITY ANALYSIS EXPECTED IN Q3 2026 Source text: ID:nGNX1Ht5k Further company coverage: OSE.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ose Immunotherapeutics SA
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Brief: OSE Immunotherapeutics SA Appoints Thomas Gidoin As Deputy CEO
Brief: Ose Immunotherapeutics Will Pause Development Of OSE‑230
Brief: OSE Immunotherapeutics Gets Second Positive IDMC Nod For Phase 3 Lung Cancer Trial
Brief: OSE Immunotherapeutics Announces Appointment Of Marc Le Bozec As Interim CEO